Indivior Pharmaceuticals (INDV) Revenue (2024 - 2026)

Indivior Pharmaceuticals has reported Revenue for 3 years, with the latest figure at $343.0 million in Q2 2026.

• On a quarterly basis, Revenue rose 13.58% year-over-year to $343.0 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 13.46% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 4.29% from the prior year.
• Revenue was $343.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $317.0 million in the prior quarter.
• The five-year high for Revenue was $358.0 million in Q4 2025, with the low at $266.0 million in Q1 2025.
• Average Revenue over 3 years is $308.9 million, with a median of $304.5 million recorded in 2024.
• The largest YoY upside for Revenue was 19.73% in 2025 against a maximum downside of 6.34% in 2025.
• Over 3 years, Revenue stood at $299.0 million in 2024, then advanced by 19.73% to $358.0 million in 2025, then dropped by 4.19% to $343.0 million in 2026.
• The last three Revenue figures came in at $343.0 million (Q2 2026), $317.0 million (Q1 2026), and $358.0 million (Q4 2025), per Business Quant data.